$249.99
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
PNC-27 30mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
PNC-27 30mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 1159861-00-3 |
|---|---|
| Purity | ≥99% |
| Sequence | Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly |
| Molecular Formula | C188H293N53O44S |
| Molecular Weight | 4031.73 g/mol |
| Applications | Oncology studies, tumor necrosis assays, HDM-2 binding research, selective anti-cancer mechanisms |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
This Pure Lab Peptides product-page guide is written for researchers evaluating where to buy PNC-27 for research while keeping the decision focused on documentation, analytical verification, and research-use-only boundaries. PNC-27 is discussed here as a synthetic peptide entity with published literature around peptide identity, p53-derived sequence context, HDM-2 research models, and membrane-focused in vitro observations. This page does not present product-use guidance, clinical claims, consumer outcomes, or personal-use positioning.
Researchers who plan to buy PNC-27 for research should first review the compound name, peptide sequence, lot-specific COA, purity data, identity testing, label consistency, and RUO positioning. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Literature context should support research interpretation, not product claims.
The first checkpoint is identity consistency. A PNC-27 product page should align with the compound name, catalog identity, batch or lot number, certificate of analysis, and any analytical files attached to that lot. PubChem lists PNC-27 as a defined peptide compound, so product documentation should not treat the name as a vague category label [1].
The COA should be batch-specific. It should show a lot number, testing date, purity value, analytical method, and identity data when available. FDA analytical-method guidance describes identity, quality, purity, and related attributes as documentation areas supported by analytical procedures in regulated drug contexts; for RUO procurement, those same concepts are useful as documentation checks, not as product claims [4].
The search phrase buy PNC-27 should be reframed as buy PNC-27 for research. That change matters because a research buyer is not looking for consumer claims; the practical task is to verify whether the research material listing is backed by transparent documentation.
For a product-page article, commercial intent can be served safely by answering procurement questions: What is the peptide identity? What does the COA show? Does the lot number match? Are HPLC and LC-MS data available? Are the claims limited to research, analytical, and literature context?
RUO labeling should be clear before any supplier comparison begins. Federal labeling rules for certain laboratory products include the statement “For Research Use Only. Not for use in diagnostic procedures,” which shows why intended-use language must remain narrow and documentation-focused [5]. FDA guidance also notes that labeling, package materials, and descriptive language may be considered when evaluating intended use for RUO-labeled IVD products [6].
For PNC-27 research pages, this means product copy should avoid converting literature phrases into product positioning. It should keep attention on COA availability, analytical testing, compound characterization, and lot-level traceability.
PNC-27 is a defined peptide compound with a published research record focused on p53-derived peptide structure and HDM-2 or MDM2-associated membrane models [1] [2]. In research literature, HDM-2 is commonly discussed as the human MDM2 protein, an E3 ubiquitin ligase that interacts with p53/TP53 biology [7] [8].
PNC-27 is listed in PubChem with molecular formula C188H293N53O44S and molecular weight of about 4032 g/mol [1]. That makes molecular identity, molecular weight, and sequence documentation important product-page fields for a research peptide.
The related literature frames PNC-27 as a peptide containing a p53-derived HDM-2 binding segment joined to a cell-penetrating or membrane-residency sequence [3]. General cell-penetrating peptide literature describes CPPs as short peptide sequences studied for movement across biological membranes and cargo-related research applications, though mechanisms and model interpretation can vary [9] [10].
The peptide sequence field is central to identity review. PubChem identifies the compound name as H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH [1].
A product page does not need to over-explain the sequence, but it should make the sequence traceable. Researchers can compare the product listing, COA, and any LC-MS or mass documentation against the expected peptide identity.
The characteristics of PNC-27 that matter for procurement are not promotional claims. They are documentation fields: peptide name, sequence, molecular formula, molecular weight, purity value, analytical method, physical form, storage notation, and lot identity.
A strong research material listing should show the compound name as PNC-27, identify it as a peptide, and make batch documentation easy to locate. PubChem’s molecular formula and molecular weight can serve as identity reference points during document review [1].
Research buyers should also look for clear wording around product category. For this page, PNC-27 fits a Cellular Pathway Research lane because the literature centers on membrane-associated protein interaction models, cancer cell line systems, necrosis markers, and cell lysis observations [2] [3].
The form of PNC-27 should be recorded consistently across the listing, label, COA, and storage documentation. If a listing describes a lyophilized research material, that description should match supplier documentation and storage notes.
The point is traceability. A physical-form statement is not a claim of research performance; it is a documentation detail that helps the lab record match the material received.
Research-use-only framing turns a commercial page into a documentation guide. The page can answer product-selection questions without presenting product claims.
RUO copy should emphasize identity, purity, COA availability, analytical testing, batch specificity, label consistency, and published literature boundaries. It should not convert model findings into product positioning.
This distinction matters because some research papers use phrases such as anticancer peptide in the title or abstract. On an RUO product page, that phrase should be treated as literature language, not a claim about the research material [2] [3].
Supplier documentation supports commercial research intent by reducing ambiguity. A research buyer can compare the product page, COA, lot number, and analytical records before selecting a material.
A useful internal procurement review asks whether the documentation answers four questions: Is the compound identity clear? Is the purity method listed? Does the lot number match? Does the page remain within RUO boundaries?
PNC-27 literature is tied to p53 and HDM-2 context. TP53 encodes p53, a tumor suppressor protein with functions related to transcriptional regulation and cell-cycle control in biological systems [11]. MDM2 encodes a protein that can bind p53 and mediate p53 ubiquitination, which helps explain why p53-MDM2 interaction models appear in this research lane [7] [8].
The structural background matters because PNC-27 literature discusses an HDM-2 binding segment derived from p53. The RCSB Protein Data Bank entry 1YCR describes MDM2 bound to the transactivation domain of p53, giving researchers a structural reference point for p53-MDM2 peptide interaction context [12].
The 2022 PNC-27 study used conformational modeling to examine how PNC-27 may bind HDM-2 in a p53 peptide-like structure [3]. For an RUO product page, the safe interpretation is that published literature provides a research model, not a product claim.
HDM-2 and MDM2 naming can create confusion. MDM2 is the official gene symbol, while HDM-2 is often used in human-protein literature [8]. UniProt describes human MDM2 as an E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53 [7].
PNC-27 research differs from classic nuclear p53-MDM2 discussion because several studies examine membrane-associated HDM-2 in cell model systems [2] [13]. That distinction should be explained carefully and kept in research context.
PNC-27 literature often centers on cancer cell membrane models. Researchers have examined whether HDM-2 is present at the plasma membrane in selected cancer cell lines and whether PNC-27 colocalizes with that membrane-associated protein in model systems [2] [14].
In the 2010 PNAS study, researchers reported that PNC-27 targeted HDM-2 in membranes of cancer cells and described membranolysis in those experimental systems [2]. Later research extended the membrane HDM-2 concept into leukemia cell-line and ovarian cancer cell-line settings [14] [15] [16].
This language should remain model-specific. A cancer cell membrane observation in a study does not become a product-use claim.
Colocalization of PNC-27 with HDM-2 has been studied using microscopy and related experimental methods [2] [16]. In ovarian cancer cell-line research, investigators reported membrane HDM-2 expression and immunofluorescence-based visualization of PNC-27 with membrane HDM-2 in selected cell models [16].
For procurement readers, the key takeaway is not a claim of product performance. It is that the literature lane is membrane-associated HDM-2 research, so product documentation should accurately identify the peptide and avoid overstatement.
Some PNC-27 studies compare transformed and non-transformed cell models, including leukemia-related and ovarian-related systems [14] [16]. These comparisons are model-specific and depend on the cell line, assay design, detection method, and experimental conditions.
That limitation matters. A safer product-page interpretation is that normal cell comparisons help researchers understand the scope of a study model, not that they create broad product conclusions.
Mechanism language is useful only when it stays tied to published research. For PNC-27, mechanism context includes HDM-2 binding, membrane colocalization, pore formation, necrosis, and cell lysis markers in experimental systems [2] [3] [17].
Published PNC-27 studies describe the peptide binds to HDM-2 in membrane-associated cancer cell models, with researchers examining the interaction using biochemical, microscopy, and modeling approaches [2] [3]. Separate AML literature has also examined cell membrane HDM2 as an experimental target concept, which supports the broader membrane-HDM2 research lane [13].
This discussion should not be converted into product effects. The safe wording is that published literature has examined PNC-27 with HDM-2 in defined experimental models.
Pore formation, necrosis, and cell lysis are research observations used to describe membrane-disruption models. Sookraj and colleagues reported that PNC-27-induced cell lysis occurred with intact peptide in experimental systems [17]. The 2022 structural study and 2024 review further discuss transmembrane pore formation as a proposed model in the PNC-27 literature [3] [18].
In product-page copy, these terms should appear as literature interpretation, not claims. They help classify the research topic; they do not define intended product use.
PNC-27’s evidence base is mostly mechanistic, in vitro, ex vivo, and preclinical literature. In vitro data can help generate mechanistic hypotheses, but NCBI’s discussion of in vitro evidence notes that nonvalidated in vitro assays alone often function as hypothesis generators rather than broad conclusions [19].
In vitro models allow researchers to isolate cell-level variables. For PNC-27, studies have examined cell lines, membrane HDM-2 expression, LDH release, microscopy, and necrosis-related readouts [14] [15] [16].
The limitation is scope. A cell line is a model, not a full biological system, and evidence interpretation should state that model-specific findings remain limited by assay design, cell type, and laboratory conditions [19].
Leukemia appears in PNC-27 literature through K562 and acute myeloid leukemia cell-line studies. Davitt and colleagues studied a p53-null K562 leukemia cell line and reported membrane HDM-2 colocalization and necrosis-related readouts in that model [14]. Thadi and colleagues later examined membrane HDM-2 and PNC-27-related necrosis observations in U937, OCI-AML3, and HL-60 leukemia cell lines [15].
For this product page, leukemia belongs only as literature context. It should not be used to imply clinical positioning.
Ovarian cancer literature includes ex vivo and cell-line studies involving PNC-27 and HDM-2 membrane expression [16] [20] [21]. A 2024 paper also examined PNC-27 interactions involving plasma membrane-bound HDM-2 and mitochondrial membrane observations in pancreatic cancer and melanoma-related experimental settings [22].
These sources help map the research landscape. They should not be read as claims for Pure Lab Peptides materials.
Evidence interpretation should separate what a study examines from what a product page can say. A simple evidence ladder is useful: official compound identity, mechanistic literature, in vitro findings, ex vivo observations, preclinical literature, and RUO product documentation.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | Formula, molecular weight, synonyms, sequence-linked identity fields for PNC-27 [1] | Official database | Supports identity review and documentation matching |
| p53-HDM-2 context | MDM2 interaction with p53 and p53 peptide structural references [7] [12] | Protein database and structural database | Supports literature background only |
| Membrane HDM-2 models | HDM-2 membrane expression and PNC-27 colocalization in selected cell models [2] [15] [16] | In vitro and cell-line literature | Supports model-specific interpretation |
| Pore formation and lysis markers | Proposed membrane disruption, necrosis, and cell lysis observations [3] [17] [18] | Mechanistic literature and review | Does not create product claims |
| Analytical documentation | HPLC, LC-MS, purity, and identity verification concepts [4] [23] | Analytical guidance | Supports COA review and procurement diligence |
Published findings can support a research overview, terminology, model classification, and source-backed literature context. They can also help explain why PNC-27 belongs in a cellular pathway research lane.
They cannot support consumer-facing product claims, broad product effects, or clinical-use language. When the literature moves beyond the scope of RUO product use, the product page should say so clearly and return to documentation, identity, COA review, and analytical testing.
Study findings are limited by model type, experimental design, assay conditions, and source quality. This is especially important with PNC-27 because the literature uses strong biological language in the context of cancer cell models, but a product page must remain RUO-safe.
A safer framework is: literature examines; product documentation verifies; RUO language limits. That keeps research findings from becoming unsupported product positioning.
A certificate of analysis is one of the most important documents for research procurement. It should help verify whether the listed material and the tested lot are the same documented research material.
A PNC-27 COA should show product name, lot number, testing date, purity result, analytical method, and identity confirmation when available. FDA analytical-method guidance discusses the role of analytical procedures in supporting documentation of identity, quality, purity, and related attributes in regulated contexts [4].
For RUO peptide review, a COA should not be treated as a marketing badge. It is a batch-specific document that helps research buyers evaluate whether product identity and purity claims are supported by analytical data.
COA dates and lot numbers should align with the product listing and label. NIST traceability guidance cautions that a document number alone is not sufficient proof of traceability; the supporting measurement chain and documentation context matter [24].
For PNC-27, the lot number should connect the listing, COA, and any chromatogram or mass spectrum. If those elements do not match, procurement review should pause until the documentation is clarified.
Purity and identity are related, but they are not the same. A purity value can describe the proportion of a main analytical peak under a defined method, while identity verification asks whether the material matches the expected peptide.
HPLC is commonly used to assess peptide purity and related impurities in peptide reference-standard work. A 2023 study on synthetic peptide reference standards reported RP-HPLC use for lot homogeneity, stability, identity, content, and purity evaluation [25].
For PNC-27 product-page review, purity data should be tied to the method used. A percentage without method context is less useful than a COA that identifies the analytical approach and lot.
Identity confirmation should be reviewed separately from purity. LC-MS can support peptide identification by matching mass-related data and, where applicable, retention-time or fragmentation information to the expected peptide [26].
For procurement teams, identity review means comparing the expected sequence, molecular weight, and analytical data. It does not mean assuming that a single purity value answers every quality question.
Analytical testing helps connect a peptide listing to measurable documentation. HPLC, LC-MS, and mass spectrometry each provide different evidence types.
HPLC separates components under defined chromatographic conditions. In peptide reference-standard work, HPLC has been used for purity, content, lot homogeneity, and stability evaluation [25].
A research buyer should check whether the COA lists the HPLC method, reports the purity value, and provides a chromatogram when available. The key question is not whether HPLC appears as a buzzword, but whether the data support the lot under review.
LC-MS combines chromatographic separation with mass-based detection, which can support peptide identity review. ICH Q2(R2) includes LC/MS examples in analytical validation concepts and discusses analytical procedures for identity, purity, impurities, and related measurements [23].
A simple lab-test verification protocol for PNC-27 documentation is:
Lot traceability connects a research material to its supporting documents. Without lot-level alignment, a COA may not correspond to the exact material listed or received.
Lot traceability should link the product-page listing, label, COA, and analytical data. NIST emphasizes that traceability depends on supporting evidence, not merely a document number [24].
For PNC-27, the procurement record should show the same compound name and lot identifier across the listing, label, and COA. Any mismatch should be clarified before the material is selected for research inventory.
Labeling consistency reduces procurement ambiguity. The compound name should not shift between unrelated synonyms, the product category should remain research-focused, and RUO language should be visible.
A good product page does not rely on hype. It gives research buyers a clear path from compound identity to analytical documentation.
PNC-27 pages can become confusing when literature terms are copied without context. A research product page should clarify the difference between academic findings, analytical documentation, and product positioning.
Common misunderstandings include:
Pathway relevance describes why researchers study a compound in a certain model. It does not claim that the product creates a particular outcome.
For PNC-27, pathway relevance includes p53-derived peptide structure, HDM-2 or MDM2 interaction context, membrane colocalization, pore formation models, necrosis markers, and cell lysis observations in published studies [2] [3] [18]. The product-page role is to summarize that literature safely and keep commercial language tied to documentation.
Search intent can drift when buyers encounter literature language and assume it belongs in product claims. Some phrases related to product effects or product performance require careful framing because they can become claims if separated from model-specific literature context.
A safe product page brings the query back to RUO procurement. That means COA review, analytical testing, peptide identity, purity, lot traceability, and clear labeling.
Product-page copy should separate four layers: compound identity, published literature, analytical documentation, and procurement review. Each layer has a different job.
Compound identity defines what PNC-27 is. Literature explains what researchers have examined. Analytical documentation supports batch review. Procurement language helps research buyers compare supplier documentation without implying product claims.
Researchers evaluating buy PNC-27 for research queries should apply a documentation-first checklist. The goal is to select based on traceable research records rather than unsupported language.
Use this quality and documentation checklist:
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Before selecting PNC-27 for a research-use-only procurement review, compare the product-page identity fields, COA, purity method, LC-MS or mass data, lot number, and label language. Give priority to documentation clarity over claim-heavy copy.
Explore Pure Lab Peptides for RUO peptide compounds with research-focused product information and available documentation.
Research use only means PNC-27 is intended solely for laboratory research contexts. This designation clarifies that the peptide is not for human or animal consumption, therapeutic use, or personal use. Researchers should focus on in vitro models, preclinical studies, and laboratory assays to interpret the compound safely and appropriately within a research framework.
PNC-27 is not intended for human or animal consumption. The compound is strictly for research-use-only applications, with all handling and evaluation confined to controlled laboratory settings. Documentation such as batch-specific COAs and analytical testing supports research integrity rather than any clinical or therapeutic use.
Researchers should review the batch-specific COA, verify peptide identity, assess purity data, and ensure lot traceability before selecting PNC-27 for research. Confirming analytical testing methods, documentation consistency, and supplier credibility helps maintain rigorous research standards and ensures that experimental work remains compliant with RUO labeling.
HPLC and LC-MS provide analytical verification of PNC-27’s molecular identity and purity. HPLC evaluates retention time and purity profiles, while LC-MS confirms mass-to-charge ratios corresponding to the expected peptide sequence. These techniques, combined with COA documentation, allow researchers to verify compound integrity for laboratory research [4](verified source URL).
Lot traceability ensures that each PNC-27 vial can be linked back to its production batch and corresponding COA. This supports reproducibility, quality control, and documentation integrity. Researchers can confirm that the peptide’s analytical testing and storage conditions align with the batch-specific information, reinforcing compliance with RUO standards.
PNC-27 product pages should separate language related to potential effects or therapeutic claims from research-focused documentation. Terms such as cognitive, nootropic, injectable, or peptide therapy can drift into consumer or clinical-use perception. Maintaining focus on compound identity, COA review, analytical testing, lot traceability, and RUO labeling keeps the content aligned with laboratory research purposes.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: SUNY Downstate Faculty Profile
Dr. Matthew R. Pincus is a published research author whose work appears throughout the PNC-27 literature connected to HDM-2, p53-derived peptide design, and membrane-focused research models. His publications are especially relevant to the cellular pathway research context discussed in this article because they address how PNC-27 has been evaluated in model-specific peptide research, including membrane association, pore-formation concepts, and literature interpretation around HDM-2. His work provides useful background for understanding why compound characterization, published literature, and research documentation must remain distinct from product claims.
Selected publications:
Author profile: Google Scholar
Ehsan Sarafraz-Yazdi is a published author in the PNC-27 research literature, including studies that helped frame the article’s discussion of p53-derived peptide structure, HDM-2 binding models, and membrane-associated research context. His publications are directly relevant to the PNC-27 research lane because they connect peptide sequence design, HDM-2 interaction models, and cellular pathway interpretation. This work supports a careful literature-based discussion of PNC-27 while keeping product-page content focused on research-use-only documentation, compound identity, and model-specific interpretation.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around PNC-27. In Cellular Pathway Research content, terms such as nootropic, cognitive enhancement, mental clarity, brain health, nasal spray, injectable, peptide therapy, and effects of PNC-27 can drift into consumer-facing, administration-focused language, wellness language, therapeutic language, or product-claim territory when framed incorrectly. Those phrases are included only as examples of wording that requires careful separation from product positioning.
For this page, language related to efficacy of PNC-27, absorption, bioavailability, clinical outcomes, consumer outcomes, or product performance belongs only in boundary-aware literature interpretation, not as claims about a research material. The focus remains on PNC-27 identity, COA review, analytical testing, peptide purity, lot traceability, RUO labeling, batch-specific documentation, research documentation, and published literature boundaries. Model-specific research context should support careful interpretation without becoming promotional language or practical guidance.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.